peplomycin and Tongue-Neoplasms

Recent advances in chemotherapy have markedly improved the treatment results for oral cancer. Among many chemotherapeutic regimens, the usefulness of multiple combination chemotherapy with cisplatin as the primary drug has been frequently reported. During the past 6-year period, we have performed combination chemotherapy with cisplatin as the primary drug, peplomycin, and etoposide (CPE chemotherapy) as one of the chemotherapeutic regimens for oral cancer. The subjects were 11 patients (7 males and 4 females) with tongue cancer treated by CPE chemotherapy as neoadjuvant chemotherapy at our department between March, 1990 and April, 1995.. PR in 8 (73%), and NC in 3 (27%). No patient showed CR and PD. The side effects observed were reversible findings such as transient myelosuppression, nausea-vomiting, and alopecia. No patient showed severe or persistent suppression of hematopoietic function.

Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Peplomycin; Tongue Neoplasms; Vomiting

Combined chemotherapy (PP therapy) using cisplatin (CDDP) and peplomycin (PEP) was performed as induction chemotherapy for 31 patients with cancer of the tongue, and the clinical and histopathological effects were investigated. As the primary clinical effect, complete response (CR) was observed in three cases, partial response (PR) in 20 cases, minor response (MR) in six cases and no change (NC) in two cases, with a clinical response rate of 74.2%. The histopathological effects of the chemotherapy in the following cases showed these histological Grades: 0 or I in four cases, IIa in 12 cases, IIb in eight cases, III in six cases and IV in one case. Fifteen of the 31 patients who received PP therapy showed a histological Grade of IIb or better, representing 48.4% of the histopathological response rate. With regard to the mode of invasion of the tumor, the histopathological response rate was 90.0% in patients with invasive Grades 1 and 2, 41.7% in those with invasive Grade 3 and 16.7% in those with invasive Grade 4C. There were no patients with invasive Grade 4D in whom the therapy was histopathologically effective. In other words, the histopathological effect significantly decreased as the invasive Grade increased. With regard to the relationship between clinical effects and histopathological effects, there was one CR patient who showed a histological Grade of IIa. Thus, it is noteworthy that clinical effects were not necessarily consistent with post-chemotherapeutic histopathological effects.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Peplomycin; Tongue Neoplasms

A new bleomycin derivative NK631 was administered in five cases of advanced recurrent oral carcinoma. The visible improvement of the tumor was noted in three cases, and in the cases of lower lip carcinoma the tumor completely disappeared, however, there was no effective change in cases of cervical metastases of the floor of the mouth and tongue carcinoma. The peripheral lymphocyte counts and serum proteins disclosed a characteristic decrease, serum proteins decreased in the albumin fraction and slightly increased in alpha 2-globlin fraction. Main side effects of NK 631 were skin exanthema, alopecia, anorexia, pyrexia, fatigue and bleeding from the tumor lesion. Regarding the lung function, the vital capacity did not change, but PaO and PaCO in blood gas analysis were together observed to slightly decrease, and it may be supposed that the influence of NK631 on the lung function cannot be neglected. T-cell ratio, lymphocyte blastoformation following PHA stimulation, PPD and DNCB skin tests, and phagocytosis test of peripheral leucocytes were studied. The immuno-suppressive effect of KK631 was the same or weak as bleomycin.

Topics: Aged; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Female; Humans; Immunologic Techniques; Lip Neoplasms; Lymphocytes; Male; Middle Aged; Mouth Neoplasms; Peplomycin; Tongue Neoplasms

The presence or absence of metastasis bears an important influence on the prognosis of head and neck cancer patients. Neoadjuvant chemotherapy has become widely employed as an initial treatment. However, the actual effectiveness of neoadjuvant chemotherapy on metastasis is still unestablished. Therefore, using an orthotopic implantation model in which cervical lymph node metastasis of oral squamous cell carcinoma can be reproduced, we investigated the inhibitory effect of neoadjuvant chemotherapy on metastasis. A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19 cells, was implanted into the tongues of nude mice. After implantation, the mice were divided into four groups: S (surgery), C+S (preoperative chemotherapy+surgery), S+C (surgery+postoperative chemotherapy), and a control (nontreatment) groups. The treatment (tumor resection or chemotherapy) was started 7 days postimplantation. The effects of each treatment on cervical lymph node metastasis were investigated by examining the rate of lymph node metastasis formation at 28 days postimplantation. In the control group, five of the 11 mice died of cachexia before the end of the experiment. However, all mice in the S, C+S, and S+C groups survived until 28 days after implantation. The cervical lymph node metastasis rates were 81.8% in S, 18.1% in C+S, 63.6% in S+C, and 100% in control groups. Thus, metastasis to the cervical lymph node was markedly inhibited by the combination of neoadjuvant chemotherapy and tumor resection. The findings of this study indicate that neoadjuvant chemotherapy is effective for inhibiting metastasis, and that it is necessary to begin chemotherapy as early as possible to achieve an inhibitory effect on metastasis. Considering these effects, if anticancer drugs are used, better therapeutic results can be expected.

Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Female; Humans; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Neck; Neoadjuvant Therapy; Peplomycin; Tongue Neoplasms; Treatment Outcome

The purposes of the present study were to analyze our experience with preoperative chemoradiotherapy followed by surgery for advanced tongue carcinoma and to assess the prognostic value of response to preoperative therapy in these tumors.. Between May 1988 and December 1999, a total of 43 patients with advanced but potentially resectable squamous cell carcinoma of the tongue were candidates for this study. A minimum tumor size of 3 cm was required. The mean age was 59.8 years (range, 26-85 years); 13 cases were advanced stage II, 23 cases were stage III, and 7 cases were stage IV. All patients were treated preoperatively with cisplatin- or carboplatin-based chemotherapy in combination with simultaneous irradiation to a target volume of 40 Gy; 2-6 weeks later, they underwent curative surgery. Tumor regression rate, residual tumor grade, and histologic regression grade to the preoperative therapy were analyzed to determine their influence on the prognosis.. With a median follow-up of 60.5 months, overall survival rates were 86.0% for all cases, 92.3% for stage II cases, 77.3% for stage III cases, and 100% for stage IV cases. The progression-free survival rates according to tumor regression rate were 33.3% for group 1 (< 50% tumor regression), 66.7% for group 2 (> or = 50% and < 75% regression), 100% for group 3 (> or = 75% and < 100% regression), and 96.0% for group 4 (complete regression). The higher the tumor regression rates, the higher the survival rates. When patients who achieved a regression rate of 75% or higher were compared with those who did not, there was a significant difference in survival (P < .0001). The factors of residual tumor grade and histologic regression grade also had good correlations with the prognosis (residual tumor grade, P =.0324; histologic regression grade, P < .0001).. The findings of the present study suggest that response to preoperative chemoradiotherapy, such as tumor regression rate, residual tumor grade, and histologic regression grade, could be of prognostic value in patients with tongue carcinoma.

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Peplomycin; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Tongue Neoplasms

A 70-year-old male complained of a mass on the left side of his tongue. A biopsy specimen was diagnosed as verrucous carcinoma. He was treated with preoperative chemotherapy (UFT, CDDP, PEP) and irradiation, continuous partial glossectomy. The tumor response to chemotherapy was excellent, and no tumor cells were found in the surgical specimen. There was no recurrence of the tumor 1 year and 7 months after therapy. For advanced tumors, preoperative chemotherapy appears to be significantly effective.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Papillary; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Humans; Male; Peplomycin; Preoperative Care; Radiotherapy Dosage; Tegafur; Tongue Neoplasms; Uracil

Speech intelligibility has been investigated in 40 patients who had received a glossotomy because of tongue and/or mouth floor carcinomas after preoperative induction therapy. The results are summarized below. 1. Speech was clearer and better understood in intelligibility tests than by tests of single sounds. 2. Speech intelligibility was impaired in 12 patients. The impairment degree was mild (slight difficulty in understanding the spoken content) in 9 cases, where as the speech in the remaining patients was moderately or severely impaired. 3. Hardly any speech impairment resulted when the tongue resection was limited to the ipsilateral 1/3 of the tongue, where as the impairment was greater in cases who received a glossotomy over that limit. 4. Tongue mobility was related to speech intelligibility, and conservation of the tongue tip appeared important. 5. Aggressive induction therapy made limited surgical extirpation possible, and many patients speech functions were well preserved by conservative surgery. Together with good local control, aggressive induction therapy seemed to be beneficial for tongue and mouth-floor carcinomas.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Mouth Neoplasms; Peplomycin; Preoperative Care; Radiotherapy Dosage; Speech Intelligibility; Tongue; Tongue Neoplasms

From 1977 to 1988, 61 patients have received radical treatment for a carcinoma of the mobile tongue. Fifty-nine of these patients were treated in association with a BLM (or PEP), and 26 patients with external irradiation. The local tumor control rate at two years was 77%, and subsequent lymph node metastasis was 25%. The five year cumulative survival rate was 55% and the main causes of death were found to be regional node metastases and other related diseases particularly. The determinate survival for TxN0 tumors was 83%. Six percent and 26% had radio-osteonecrosis and soft tissue necrosis respectively and three patients required surgery.

Topics: Adult; Aged; Aged, 80 and over; Bleomycin; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Evaluation Studies as Topic; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Osteoradionecrosis; Peplomycin; Radiation Injuries; Remission Induction; Tongue Neoplasms

Topics: 4-Nitroquinoline-1-oxide; Animals; Bleomycin; Carcinoma; Peplomycin; Rats; Rats, Inbred Strains; Tongue Neoplasms

Topics: 4-Nitroquinoline-1-oxide; Animals; Bleomycin; Epithelium; Peplomycin; Rats; Rats, Inbred Strains; Tongue; Tongue Neoplasms

Fifty-three patients with postoperative recurrent epidermoid carcinomas of the head and neck were treated with BEAM, DP, MBD and CAP regimens. Complete response (CR) and partial response (PR) were achieved in 9% and 23% of all evaluable patients, respectively. Especially, in patients with oral cancer (17 cases), the response rate was only 23% (CR 0%, PR 23%). From our results, it was concluded that chemotherapy in any form must be palliative for a patient who has received prior unsuccessful radiotherapy or surgery. For previously untreated patients who present with Stage III or IV advanced carcinoma, combination chemotherapy with CDDP, MTX and PEP should be considered as the initial method of treatment. Adjuvant chemotherapy and intra-arterial chemotherapy for oral cancer should also be considered. Adjuvant chemotherapy combined with UFT and MTX is indicted to be effective for the prevention of local recurrence and micrometastases, but a further randomized study is necessary to confirm these findings.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Administration Schedule; Female; Humans; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Peplomycin; Tongue Neoplasms

Topics: Animals; Bleomycin; Carcinoma; Cricetinae; Floxuridine; Kinetics; Male; Mesocricetus; Peplomycin; Tissue Distribution; Tongue Neoplasms

Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Kinetics; Maxillary Neoplasms; Peplomycin; Tongue Neoplasms